Clinical Trials Logo

Filter by:
NCT ID: NCT03796377 Completed - Clinical trials for Drug Interaction Study

Rivaroxaban Hypericum Trial

Start date: February 13, 2019
Phase: Phase 1
Study type: Interventional

Single-center, open-label, sequential treatment study to investigate the influence of the combined P-glycoprotein and CYP3A4 inducer hypericum perforatum on the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy volunteers.

NCT ID: NCT03796000 Completed - Metabolic Disease Clinical Trials

Characterization of Human Intestinal Macrophages in Metabolic Disease

iMAC
Start date: May 14, 2018
Phase:
Study type: Observational

This is a prospective, observational study aiming at improving the understanding of the pathophysiology of metabolic disease. As inflammation has been recognized as a key characteristic of metabolic disease but its starting point is still unknown, the investigators' aim is to characterize intestinal macrophages from human gut biopsies taken in diagnostic endoscopies of the gastrointestinal tract or in bariatric surgeries for clinical reasons.

NCT ID: NCT03794544 Completed - NSCLC Clinical Trials

Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer

Start date: March 8, 2019
Phase: Phase 2
Study type: Interventional

Study D9108C00002 (NeoCOAST) is a platform study assessing the effectiveness and safety of neoadjuvant durvalumab alone or in combination with novel agents in participants with resectable, early-stage (Stage I [>2cm] to IIIA) non-small cell lung cancer (NSCLC).

NCT ID: NCT03792490 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS

ROCK-ALS
Start date: February 20, 2019
Phase: Phase 2
Study type: Interventional

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder and therapeutic options are limited. The rho kinase (ROCK) inhibitor Fasudil was shown to be neuroprotective, induced axonal regeneration and improved survival and behavioral outcome in models of ALS and other neurodegenerative diseases. The aim of this phase IIa, multi-center and double-blind study is to analyze the safety, tolerability and efficacy of fasudil in two different doses compared to placebo in approximately 16 trial sites in Germany, France and Switzerland. Intravenous application of fasudil will be performed in 80 patients and placebo in 40 patients two times daily for 20 treatment days. The hypothesis is that fasudil is safe and well-tolerated and its application will significantly improve the clinical outcome in patients with ALS.

NCT ID: NCT03792464 Completed - Anemia Clinical Trials

Serum Hepcidin in Pregnant Women and the Association With Pregnancy Outcome

Start date: April 30, 2019
Phase:
Study type: Observational

Hepcidin production is normally upregulated by iron stores, and in obesity has been shown to be overexpressed and correlated with low iron status. The increased hepcidin may restrain the iron release from the cells by affecting the expression of ferroportin, which probably associates with the development of diabetes complication. Firstly, investigator examines the difference of serum hepcidin and iron parameters between obese and non-obese pregnant women; secondly, the correlation between serum hepcidin and adverse maternal and neonatal outcomes in pregnant women will be tested.

NCT ID: NCT03791671 Completed - Stroke Clinical Trials

Balance Training After Stroke - a Randomized, Controled Pilot Study

Start date: March 4, 2019
Phase: N/A
Study type: Interventional

This pilot study is part of a master's thesis. In the rehabilitation of stroke patients should be compared whether individual balance training has a greater effect than group balance training. The result is determined based on the walking speed.

NCT ID: NCT03788343 Completed - Phenylketonuria Clinical Trials

Phenylalanine and Its Impact on Cognition

PICO
Start date: August 19, 2019
Phase: Phase 4
Study type: Interventional

The PICO-Study is a randomized, placebo-controlled, crossover, non-inferiority trial conducted to add evidence to the current European treatment guidelines for adult patients with phenylketonuria.

NCT ID: NCT03787199 Completed - Stroke Clinical Trials

Feasibility of the Overground Bodyweight Supporting Walking System Andago

Start date: May 28, 2018
Phase: N/A
Study type: Interventional

The overall aim of this project is to investigate the clinical utility of the Andago System, a CE certified mobile bodyweight supporting walking robot, in children with neuromotor disorders. Clinical utility encompasses practicability, acceptability, appropriateness, and accessibility. In this study, the investigators would like to investigate several aspects of clinical utility that belong to the first three components.

NCT ID: NCT03786198 Completed - Early Breast Cancer Clinical Trials

Activity Program During Aromatase Inhibitor Therapy

Start date: March 28, 2019
Phase: N/A
Study type: Interventional

The primary aim of the trial is to investigate if a simple outdoor walking intervention, which is practicable under real-life conditions, beginning at the start of adjuvant aromatase inhibitor (AI) therapy, can prevent the occurrence of muscle or joint pain/stiffness in breast cancer patients.

NCT ID: NCT03785912 Completed - Mental Disorder Clinical Trials

SelFIT: Internet-based Treatment for Adjustment Problems After an Accident

SelFIT
Start date: December 18, 2019
Phase: N/A
Study type: Interventional

In this study, people who suffer from adjustment problems after having experienced an accident will be randomized to one of two study groups. The first group receives access to the internet-based self-help intervention immediately. The second group is a waiting control group that receives access to the program 12 weeks later. In both conditions additional care or treatment is allowed. The aim of the study is to investigate the efficacy and cost-effectiveness of an internet-based self-help intervention for people with adjustment problems after an accident compared to a waiting list. There are 6 assessments, which all take place online: baseline, two between-measurements (after 4 and 8 weeks), post assessment (after 12 weeks) and two follow-up assessments (after 3 and 6 months). All participants from both groups are asked to fill out all assessments.